Anil Abraham Joy


Faculty of Medicine & Dentistry - Oncology Dept


Area of Study / Keywords


Dr. Joy currently serves as a Professor of Oncology. Division of Medical Oncology, Faculty of Medicine and Dentistry at the University of Alberta and also as a staff Medical Oncologist at the Cross Cancer Institute in Edmonton, Alberta.


He received his Bachelor of Science Degree (Honours with Distinction, Specialization in Pharmacology) and Medical Doctorate (Honours with Distinction) from the University of Alberta.  He is certified by the Royal College of Physicians and Surgeons of Canada as a specialist in Internal Medicine with sub-specialty certification in Medical Oncology.  

Dr. Joy was awarded with a Future Leaders of Oncology (FLO) award in 2011 and has since completed and obtained 8 Certificates of Achievement within the Physician Management Institute (PMI) - Canadian Medical Association.  He was also chosen and completed the inaugural Academic Leadership Development Program at University of Alberta in 2013.

His primary oncologic care interests include Breast and Thoracic malignancies. 

He is actively involved in patient care, clinical research, medical education, cancer survivorship / well-being, cancer advocacy and global/regional oncology disparity issues and has peer-reviewed publications in these areas.

He is involved in numerous local, university, provincial and national committees.  He has served as a medical advisor to both the Comprehensive Breast Care Program (Edmonton) and the Hereditary Breast and Ovarian Cancer Society (Alberta).  He is a Scientific Advisory Council member to Rethink Breast Cancer and serves on the Wellspring Healthcare Advisory Committee (Edmonton). 

He is actively involved with the Canadian Clinical Trials Group, and serves as National Chair for the CCTG MA.38 metastatic breast cancer clinical trial.

His former appointments include serving on the Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer, past Chair of the Northern Alberta Breast Cancer Program, Medical Director (Edmonton) of the Alberta Cancer Research Biobank (former CBCF Tumor Bank), pan-Canadian Working Group on Primary Care and Oncology Care Integration (Canadian Partnership Against Cancer) as well as Provincial Chair of the Alberta Breast Cancer Program. 


Most recently, he was appointed to the pan-Canadian Oncology Drug Review (pCODR) Canadian Agency for Drugs and Technologies in Health (CADTH) where he serves on the Expert Review Committee (pERC) where they assess the clinical evidence and cost-effectiveness of cancer drugs in order to make recommendations to help guide drug funding decisions across Canada.


  • Phase II / III Clinical Trials – Breast and Thoracic Malignancies
  • Cancer Biology, Exercise–Cardiovascular–Oncology Research, REthining Clinical Trials (REaCT)
  • Hereditary Breast Cancer, Breast Cancer in Young Women, Cancer Survivorship
  • Oncology Drug Approval, Cancer Guideline Development
  • Global Oncology and Regional Disparity Issues 
  • Medical / Public Education
  • Well-being

Featured Publications

Tandon P., Purdy G., Ismond K.P., Cruz C., Etruw E., Suderman K., Hyde A., Stickland M., Spence J.C., Lien D.C., Bhanji R., Prado C.M., Cruz A.M., Joy A.A., Yaskina M., Round J., Harback K., Padwal R., McNeely M.L.

Contemporary Clinical Trials. 2022 May; 118 10.1016/j.cct.2022.106791

Kirkham A.A., Ford K.L., Topolnyski J., Da Silva B.R., Paterson D.I., Prado C.M., Joy A.A., Boulé N.G., Pituskin E., Haykowsky M.J., Thompson R.B.

JACC: CardioOncology. 2022 May; 4 (2):276-278 10.1016/j.jaccao.2022.03.002

McNeely M.L., Suderman K., Yurick J.L., Nishimura K., Sellar C., Ospina P.A., Pituskin E., Lau H., Easaw J.C., Parliament M.B., Joy A.A., Culos-Reed S.N.

Cancers. 2022 May; 14 (11) 10.3390/cancers14112737

Ferrario C., Christofides A., Joy A.A., Laing K., Gelmon K., Brezden-Masley C.

Current Oncology. 2022 April; 29 (4):2720-2734 10.3390/curroncol29040222

Oberoi D., Kwok C., Li Y., Railton C., Horsman S., Reynolds K., Joy A.A., King K.M., Lupichuk S.M., Speca M., Culos-Reed N., Carlson L.E., Giese-Davis J.

BMC Medical Research Methodology. 2022 March; 22 (1) 10.1186/s12874-022-01549-1

Gandhi S., Brackstone M., Hong N.J.L., Grenier D., Donovan E., Lu F.I., Skarpathiotakis M., Lee J., Boileau J.F., Perera F., Simmons C., Joy A.A., Tran W.T., Tyono I., Van Massop A., Khalfan S.

BREAST CANCER RESEARCH AND TREATMENT. 2022 February; 193 (1) 10.1007/s10549-022-06522-6

SERENA-4: Phase III Trial of AZD9833 + Palbociclib Versus Anastrozole + Palbo-Ciclib in ER+/HER2- Advanced Breast Cancer

Japanese Society of Medical Oncology - Annual Meeting. 2022 February;

Simmons C., Rayson D., Joy A.A., Henning J.W., Lemieux J., McArthur H., Card P.B., Dent R., Brezden-Masley C.

Therapeutic Advances in Medical Oncology. 2022 January; 14 10.1177/17588359211066677

Elevated plasma IL-8 predicts for reduced outcomes in CCTG MA.38, a phase 2 randomized trial of palbociclib in ER+/HER2- metastatic breast cancer patients

San Antonio Breast Cancer Symposium. 2021 December;

SERENA-4: A Phase III comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive/HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease.

San Antonio Breast Cancer Symposium. 2021 December;

Clinical Nutrition ESPEN. 2021 December; 10.1016/j.clnesp.2021.09.658

Leighl N.B., Laurie S.A., Goss G.D., Hughes B.G.M., Stockler M., Tsao M.S., Hwang D.M., Joubert P., Kulkarni S., Blais N., Joy A.A., Mates M., Rana P., Yadav S.K., Underhill C., Lee C., Bradbury P.A., Hiltz A., Dancey J., Ding K., Vera-Badillo F.

Journal of Thoracic Oncology. 2021 November; 17 (3):434-445 10.1016/j.jtho.2021.10.023

Weekday 16:8 Time-Restricted Eating in Breast Cancer Survivors: Feasibility, Safety, and Effects on Cardiometabolic Health

American Heart Association. 2021 November;

Zhu Z., Wang W., Lin F., Jordan T., Li G., Silverman S., Qiu S., Joy A.A., Chen C., Hockley D.L., Zhang X., Zhou Q., Postovit L.M., Zhang X., Hou Y., Mackey J.R., Li B., Wong G.K.S.

Cell Reports Medicine. 2021 October; 2 (10) 10.1016/j.xcrm.2021.100404

A Novel Composite Biomarker Panel For Detection Of Early Stage Non-Small Cell Lung Cancer

CARO 2021, Journal of the European Society for Radiotherapy and Oncology. 2021 October;

Kirkham A.A., King K., Joy A.A., Pelletier A.B., Mackey J.R., Young K., Zhu X., Meza-Junco J., Basi S.K., Hiller J.P., Brkin T., Michalowski B., Pituskin E., Paterson D.I., Courneya K.S., Thompson R.B., Prado C.M.

BMC CANCER. 2021 October; 21 (1) 10.1186/s12885-021-08808-2

Miles D., Ciruelos E., Schneeweiss A., Puglisi F., Peretz-Yablonski T., Campone M., Bondarenko I., Nowecki Z., et al.

ANNALS OF ONCOLOGY. 2021 October; 32 (10):1245-1255 10.1016/j.annonc.2021.06.024

Gelmon K., Walshe J.M., Mahtani R., Joy A.A., Karuturi M., Neven P., Lu D.R., Kim S., Schnell P., Bananis E., Schwartzberg L.

BREAST. 2021 October; 59 10.1016/j.breast.2021.07.017

Effect Of Palbociclib (PAL) + Endocrine Therapy (ET) On Time To Chemotherapy (TTC) Across Subgroups Of Patients (Pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer (ABC): Post Hoc Analyses From PALOMA-2 (P2) And PALOMA-3 (P3).

ESMO Conference 2021. 2021 September;

Clemons M., Liu M., Stober C., Pond G., Jemaan Alzahrani M., Ong M., Ernst S., Booth C., Mates M., Abraham Joy A., Aseyev O., Blanchette P., Vandermeer L., Tu M., Thavorn K., Fergusson D.

Journal of Bone Oncology. 2021 September; 30 10.1016/j.jbo.2021.100388

Clemons M., Fergusson D., Joy A.A., Thavorn K., Meza-Junco J., Hiller J.P., Mackey J., Ng T., Zhu X., Ibrahim M.F.K., Sienkiewicz M., Saunders D., Vandermeer L., Pond G., Basulaiman B., Awan A., Pitre L., Nixon N.A., Hutton B., Hilton J.F.

Breast Journal. 2021 August; 58 10.1016/j.breast.2021.03.012

Pituskin E., Joy A.A., Fairchild A.

Seminars in Oncology Nursing. 2021 August; 37 (4) 10.1016/j.soncn.2021.151176

Tu M.M., Clemons M., Stober C., Jeong A., Vandermeer L., Mates M., Blanchette P., Joy A.A., Aseyev O., Pond G., Fergusson D., Ng T.L., Thavorn K.

Current Oncology. 2021 June; 28 (3):1847-1856 10.3390/curroncol28030171

journal of clinical oncology. 2021 May; 10.1200/JCO.2021.39.15_suppl.TPS1101

Bedard E.L.R., Abraham A.G., Joy A.A., Ghosh S., Wang X., Lim A., Shao D., Loebenberg R., Roa W.H.

Clinical and Investigative Medicine. 2021 March; 44 (1):E15-E24 10.25011/cim.v44i1.36016

Joy A.A., Vos L.J., Pituskin E., Cook S.F., Bies R.R., Vlahadamis A., King K., Basi S.K., Meza-Junco J., Mackey J.R., Stanislaus A., Damaraju V.L., Damaraju S., Sawyer M.B.

Clinical Breast Cancer. 2021 March; 10.1016/j.clbc.2021.03.001

SABCS 2020, AACR, CANCER RESEARCH. 2021 February; 10.1158/1538-7445.SABCS20-PS10-14

LeVasseur N., Cheng W., Mazzarello S., Clemons M., Vandermeer L., Jones L., Joy A.A., Barbeau P., Wolfe D., Ahmadzai N., Hersi M., Stober C., Shorr R., Hilton J., Hutton B.

PLoS One. 2021 February; 16 (2 February) 10.1371/journal.pone.0245794

Clemons M., Ong M., Stober C., Ernst S., Booth C., Canil C., Mates M., Robinson A., Blanchette P., Joy A.A., Hilton J., Aseyev O., Pond G., Jeong A., Hutton B., Mazzarello S., Vandermeer L., Kushnir I., Fergusson D.

EUROPEAN JOURNAL OF CANCER. 2021 January; 142 10.1016/j.ejca.2020.08.019